Skip to main content
Premium Trial:

Request an Annual Quote

LumiraDx Receives Notice From Nasdaq Over Missed Listing Requirement

NEW YORK — LumiraDx said on Tuesday that it has been notified by the Nasdaq that its shares are out of compliance with the stock exchange's $1 minimum bid price requirement.

According to LumiraDx, the closing price of its common shares on the Nasdaq was below $1 for 30 consecutive trading days, setting the stock up for delisting. The UK-based point-of-care diagnostics maker said it has until July 26 to regain compliance with the requirement, which involves the stock closing at or above $1 for at least 10 consecutive trading days.

LumiraDx said that it will monitor the closing bid price of its shares and evaluate its options to regain compliance with the Nasdaq listing requirement.

In November, LumiraDx reported a 61 percent year-over-year drop in third quarter revenues and said that it had begun a restructuring plan designed to save around $18 million a quarter.

During early Wednesday morning trading, shares of LumiraDx were up almost 0.5 percent to $.94.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.